Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05480384 |
| Title | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2- Positive Cancers of the Esophagus and Gastroesophageal Junction |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Brown University |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Weill Cornell Medicine/New York-Presbyterian | NOT_YET_RECRUITING | New York | New York | 10021 | United States | Details |
| Lifespan Cancer Institute | RECRUITING | Providence | Rhode Island | 02903 | United States | Details |